摘要
目的对照唑来膦酸注射液和帕米膦酸二钠注射液治疗恶性肿瘤所致高钙血症的临床疗效和安全性。方法将42例恶性肿瘤所致高钙血症的患者按随机数字表法分为治疗组(采用唑来膦酸治疗)和对照组(采用帕米膦酸二钠治疗),每组21例,分别观察治疗前、治疗后第1、4、7、14、21、28天的血钙值以及不良反应。结果治疗组和对照组治疗第7天有效率分别为85.00%(17/20)和52.38%(11/21),2组比较差异有统计学意义(P<0.05),其他时间点有效率比较差异无统计学意义(P>0.05)。2组不良反应比较差异无统计学意义(P>0.05)。结论唑来磷酸是一种新型骨质溶解抑制剂,对于恶性肿瘤所致高钙血症的患者具有更好的有效性和安全性。
Objective To compared the safety and efficacy of zoledronic acid and pamidronate disodium in the treatment of hypercalcemia due to malignancy.Methods Forty-two patients with hypercalcemia were randomly divided into zoledronic acid treatment group（n=21） and pamidronate disodium treatment group（n=21）.Blood calcium concentrations and adverse reactions were observed before treatment and on the 1st,4th,7th,14th,21st and 28th day after treatment.Results The efficacy rate in zoledronic acid treatment group（85.00%,17/20） was significantly higher than that in pamidronate disodium treatment group（52.38%,11/21） on the 7th day after treatment（P0.05）.There were no obvious differences in the incidence of adverse reactions between the two groups（P0.05）.Conclusion As a new inhibitor of bone resorption,zoledronic acid is safer and more effective than pamidronate disodium in the treatment of hypercalcemia of malignancy.
出处
《南昌大学学报（医学版）》
CAS
2011年第9期33-36,共4页
Journal of Nanchang University：Medical Sciences
